Relmada Therapeutics Financial Statements
Relmada Therapeutics Financial Overview
Relmada Therapeutics's market cap is currently ―. The company's EPS TTM is $-7.195; its P/E ratio is -3.64; Relmada Therapeutics is scheduled to report earnings on August 11, 2022, and the estimated EPS forecast is $-1.27. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ ― | $ ― | $ ― | $ ― | $ ― |
| EBIT | $ -38.30M | $ -34.18M | $ -42.65M | $ -26.46M | $ -22.41M |
| EBITDA | $ -38.30M | $ -34.18M | $ -42.65M | $ -26.46M | $ -22.40M |
| Net Income Common Stockholders | $ -39.75M | $ -34.38M | $ -42.61M | $ -26.55M | $ -22.22M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 88.09M | $ 102.70M | $ 109.07M | $ 117.09M | $ 123.14M |
| Total Assets | $ 225.81M | $ 223.33M | $ 90.93M | $ 110.77M | $ 103.87M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -88.09M | $ -102.70M | $ -109.07M | $ -117.09M | $ -123.14M |
| Total Liabilities | $ 15.41M | $ 15.06M | $ 18.25M | $ 13.92M | $ 12.72M |
| Stockholders Equity | $ 72.69M | $ 91.15M | $ 96.85M | $ 105.58M | $ 122.21M |
| Cash Flow | |||||
| Free Cash Flow | $ -19.43M | $ -37.66M | $ -20.92M | $ -17.21M | $ -16.09M |
| Operating Cash Flow | $ -19.43M | $ -37.66M | $ -20.92M | $ -17.21M | $ -16.09M |
| Investing Cash Flow | $ -10.03M | $ -91.18M | $ 27.51M | $ -5.91M | $ 15.47M |
| Financing Cash Flow | $ 29.95M | $ 161.84M | $ 185.16K | $ 23.99M | $ 1.93M |